Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Income from Non-Controlling Interests (2022 - 2024)

Historic Income from Non-Controlling Interests for Jaguar Health (JAGX) over the last 3 years, with Q2 2024 value amounting to -$136000.0.

  • Jaguar Health's Income from Non-Controlling Interests rose 354.61% to -$136000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was -$559000.0, marking a year-over-year increase of 5270.73%. This contributed to the annual value of -$759000.0 for FY2024, which is 2628.95% down from last year.
  • As of Q2 2024, Jaguar Health's Income from Non-Controlling Interests stood at -$136000.0, which was up 354.61% from -$142000.0 recorded in Q1 2024.
  • Jaguar Health's 5-year Income from Non-Controlling Interests high stood at -$23000.0 for Q2 2022, and its period low was -$651000.0 during Q4 2022.
  • In the last 3 years, Jaguar Health's Income from Non-Controlling Interests had a median value of -$140000.0 in 2023 and averaged -$182000.0.
  • Data for Jaguar Health's Income from Non-Controlling Interests shows a peak YoY increase of 7864.82% (in 2023) and a maximum YoY decrease of 51304.35% (in 2023) over the last 5 years.
  • Jaguar Health's Income from Non-Controlling Interests (Quarter) stood at -$651000.0 in 2022, then surged by 78.65% to -$139000.0 in 2023, then grew by 2.16% to -$136000.0 in 2024.
  • Its Income from Non-Controlling Interests stands at -$136000.0 for Q2 2024, versus -$142000.0 for Q1 2024 and -$139000.0 for Q4 2023.